Intrahepatic mass-forming cholangiocarcinoma: enhancement pattern on Gd-BOPTA-MRI with emphasis of hepatobiliary phase

Mamone, Giuseppe; Marrone, Gianluca; Caruso, Settimo; Carollo, Vincenzo; Gentile, Giovanni; Crinò, Francesca; Milazzo, Mariapina; Luca, Angelo

doi:10.1007/s00261-015-0445-5

Cited by 25 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intrahepatic masses of cholangiocarcinoma are rich in brous tissue at the lesion center, with fewer peripheral bers, and they often manifest with progressive and centripetal enhancement. Three typical enhancements have been reported [23]: 1) edge enhancement during the arterial phase with delayed lling; 2) heterogeneous enhancement during the early arterial phase with continuous enhancement during the delayed phase; and 3) slight peripheral enhancement during the early arterial phase with an un lled center during the delayed phase. Indirect signs include liver capsule retraction and hepatic vein embedding.…”

Section: Discussionmentioning

confidence: 90%

Comparison of the clinical and MRI features of patients with hepatic hemangioma, epithelioid hemangioendothelioma, or angiosarcoma

Liu

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background Comparisons of hepatic epithelioid hemangioendothelioma (HEHE), hepatic hemangioma, and hepatic angiosarcoma (HAS) have rarely been reported. The purpose of our study was to analyze the clinical and magnetic resonance imaging (MRI) findings of these conditions. Methods A total of 57 patients (25 with hemangioma, 13 with HEHE, and 19 with HAS) provided hepatic vascular endothelial cell data between June 2006 and May 2017. Results The proportions of cases with circumscribed margins were 88% (22/25), 84.6% (11/3), and 31.6% (6/19) for hemangioma, HEHE, and HAS, respectively (P<0.001). HAS lesions were less likely to have circumscribed margins. The proportions of lesions with hemorrhaging were 4% (1/25), 44.4% (4/13), and 36.8% (7/13) for hemangioma, HEHE, and HAS, respectively (P=0.014). HEHE and HAS cases were more likely to show heterogeneous signals on T1-weighted (T1WI) MRI. HEHE and HAS cases were more likely to show heterogeneous signals on T2-weighted (T2WI) MRI. Centripetal enhancement was the most common pattern in vascular tumors, with proportions of 100%, 46.2% (6/13), and 68.4% (13/19) for hemangioma, HEHE, and HAS, respectively. The difference in enhancement pattern between HEHE and HAS was not significant, but rim enhancement was more common for HEHE (46.2%, 6/13). Conclusions Our study revealed clinical and imaging differences between HEHE and HAS. The platelet count (PLT) and coagulation function of the HAS group decreased, whereas the alpha-fetoprotein (AFP) level increased. The 5-year survival rate for HAS was significantly lower than that of HEHE. A higher malignancy degree indicated a more blurred lesion margin, easier occurrence of hemorrhaging, and more heterogeneous plain T1WI and T2WI signals.

show abstract

Section: Discussionmentioning

confidence: 90%

Comparison of the clinical and MRI features of patients with hepatic hemangioma, epithelioid hemangioendothelioma, or angiosarcoma

Liu

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The presence of a lesser degree of central hypointensity is thought to be due to extracellular/extravascular contrast retention in the fibrotic stroma rather than active uptake by cellular transporters . Single‐center, retrospective studies report that a targetoid appearance in the TP or HBP can be seen in 42–79% of iCCAs . Additionally, a targetoid appearance on the TP/HBP is an independent predictor of iCCA, and is more common in non‐HCC malignancies than in hypovascular HCCs (86% vs. 17%, respectively) …”

Section: Gadoxetate and Li‐radsmentioning

confidence: 99%

“…118 Singlecenter, retrospective studies report that a targetoid appearance in the TP or HBP can be seen in 42-79% of iCCAs. [118][119][120][121] Additionally, a targetoid appearance on the TP/HBP is an independent predictor of iCCA, and is more common in non-HCC malignancies than in hypovascular HCCs (86% vs. 17%, respectively). 122 ANCILLARY FEATURES FAVORING MALIGNANCY IN GENERAL.…”

Section: Lr-m (Probably or Definitely Malignant Notmentioning

confidence: 99%

Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI‐RADS)

Chernyak

Fowler

Heiken

et al. 2019

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Use of gadoxetate disodium, a hepatobiliary gadolinium‐based agent, in patients with chronic parenchymal liver disease offers the advantage of improved sensitivity for detecting hepatocellular carcinoma (HCC). Imaging features of liver observations on gadoxetate‐enhanced MRI may also serve as biomarkers of recurrence‐free and overall survival following definitive treatment of HCC. A number of technical and interpretative pitfalls specific to gadoxetate exist, however, and needs to be recognized when protocoling and interpreting MRI exams with this agent. This article reviews the advantages and pitfalls of gadoxetate use in patients at risk for HCC, and the potential impact on Liver Imaging Reporting and Data System (LI‐RADS) imaging feature assessment and categorization. Level of Evidence: 5 Technical Efficacy Stage: 2 J. Magn. Reson. Imaging 2019;49:1236–1252.

show abstract

“… 26 Mass-forming ICC typically has a diameter of 5–10 cm at the time of diagnosis. 29 , 30 Intraductal ICC is a slowly growing papillary tumor and has a favorable prognosis compared with the other two types. 26 On imaging, it is a 1–2 cm mass within the bile duct with proximal ductal dilatation.…”

Section: Histologymentioning

confidence: 99%

Intrahepatic cholangiocarcinoma: current perspectives

Buettner

Vugt

IJzermans

et al. 2017

OTT

129

107

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy arising from the liver. ICC makes up about 10% of all cholangiocarcinomas. It arises from the peripheral bile ducts within the liver parenchyma, proximal to the secondary biliary radicals. Histologically, the majority of ICCs are adenocarcinomas. Only a minority of patients (15%) present with resectable disease, with a median survival of less than 3 years. Multidisciplinary management of ICC is complicated by large differences in disease course for individual patients both across and within tumor stages. Risk models and nomograms have been developed to more accurately predict survival of individual patients based on clinical parameters. Predictive risk factors are necessary to improve patient selection for systemic treatments. Molecular differences between tumors, such as in the epidermal growth factor receptor status, are promising, but their clinical applicability should be validated. For patients with locally advanced disease, several treatment strategies are being evaluated. Both hepatic arterial infusion chemotherapy with floxuridine and yttrium-90 embolization aim to downstage locally advanced ICC. Selected patients have resectable disease after downstaging, and other patients might benefit because of postponing widespread dissemination and biliary obstruction.

show abstract

Intrahepatic mass-forming cholangiocarcinoma: enhancement pattern on Gd-BOPTA-MRI with emphasis of hepatobiliary phase

Cited by 25 publications

References 24 publications

Comparison of the clinical and MRI features of patients with hepatic hemangioma, epithelioid hemangioendothelioma, or angiosarcoma

Comparison of the clinical and MRI features of patients with hepatic hemangioma, epithelioid hemangioendothelioma, or angiosarcoma

Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI‐RADS)

Intrahepatic cholangiocarcinoma: current perspectives

Contact Info

Product

Resources

About